Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Foretinib
CHF 0.00
In stock
SYN-1129-M0011 mgCHF 149.00
SYN-1129-M0055 mgCHF 227.00
SYN-1129-M01010 mgCHF 412.00
SYN-1129-M05050 mgCHF 1'206.00
SYN-1129-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | GSK-1363089; EXEL-2880 |
| Product Type | Chemical |
| Properties | |
| Formula | C34H34F2N4O6 |
| MW | 632.7 |
| CAS | 849217-64-7 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: VEGFR2 - MET | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | CXQHYVUVSFXTMY-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Foretinib is a novel MET and VEGFR2 kinase inhibitor with IC(50) values of 0.4 and 0.8nM for MET and VEGFR2 respectively.
Product References
- Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis: M. Zillhardt, et al.; Clin. Cancer Res. 17, 4042 (2011)
Related Products
